|
Cerebellar ataxia, intellectual disability, oculomotor apraxia, cerebellar cysts syndrome
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
Using a combination of homozygosity mapping and whole-exome sequencing, we identified biallelic mutations in LAMA1 as the cause of CDC in seven affected individuals (from five families) independent from those included in the phenotypic description of Poretti-Boltshauser syndrome.
|
25105227 |
2014 |
|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we found LAMB4 (11.8% of GC and 7.6% of CRC with MSI-H), LAMA3 (2.9% of GC and 2.5 of CRC with MSI-H), LAMA1 (5.9% of GC with MSI-H) and LAMB1 frameshift mutations (1.3% of CRC with MSI-H).
|
25257191 |
2015 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.
|
29907957 |
2018 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.
|
27941887 |
2017 |
|
Nonalcoholic Steatohepatitis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Nonalcoholic steatohepatitis (NASH), when compared with simple steatosis (SS), significantly increases the expression of TGFB1 (6.8, p<0.005), angiotensin I-converting enzyme (ACE) (2.1, p<0.007), LAMA1 (2.1, p<0.007), SERPINB2 (2.1, p<0.007), CSF2 (2.5, p<0.002), IL1A (2.5, p<0.005), IL3 (2.1, p<0.007), IL4 (2.1, p<0.007), LIF (2.1, p<0.007), and MMP1 (2.1, p<0.007), and decreases the transcript levels of genes involved in the negative regulation of cell-death pathways.
|
21664615 |
2011 |
|
Intellectual Disability
|
0.310 |
Biomarker
|
group |
BEFREE |
A mosaic intragenic microduplication of LAMA1 and a constitutional 18p11.32 microduplication in a patient with keratosis pilaris and intellectual disability.
|
30244536 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.120 |
Biomarker
|
disease |
BEFREE |
We also examined the association of 3 additional loci: CCND2 and GIPR, identified in sex-differentiated analyses, and LAMA1, which was shown to be associated with non-obese European type 2 diabetes.
|
25951451 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
A variant (rs8090011) in the LAMA1 gene was associated with type 2 diabetes in lean cases (P = 8.4×10⁻⁹, OR = 1.13 [95% CI 1.09-1.18]), and this association was stronger than that in obese cases (P = 0.04, OR = 1.03 [95% CI 1.00-1.06]).
|
22693455 |
2012 |
|
Retinal Dystrophies
|
0.120 |
GeneticVariation
|
group |
BEFREE |
In one additional family, we identified two siblings who have truncating LAMA1 mutations in combination with retinal dystrophy and mild cerebellar dysplasia without cysts, indicating that cysts are not an obligate feature associated with loss of LAMA1 function.
|
25105227 |
2014 |
|
Retinal Dystrophies
|
0.120 |
GeneticVariation
|
group |
BEFREE |
In this paper we describe individuals with biallelic mutations in LAMA1, all of whom had the cerebellar dysplasia, myopia and retinal dystrophy, in addition to obsessive compulsive traits, tics and anxiety.
|
27095636 |
2016 |
|
Anxiety
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
In this paper we describe individuals with biallelic mutations in LAMA1, all of whom had the cerebellar dysplasia, myopia and retinal dystrophy, in addition to obsessive compulsive traits, tics and anxiety.
|
27095636 |
2016 |
|
Myopia
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Cystic cerebellar dysplasia and biallelic LAMA1 mutations: a lamininopathy associated with tics, obsessive compulsive traits and myopia due to cell adhesion and migration defects.
|
27095636 |
2016 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent updates to the GOLD guidelines emphasize the use of combination LABA and LAMA bronchodilators for patients with chronic obstructive pulmonary disease with persistent dyspnea despite monotherapy or frequent exacerbations despite LAMA monotherapy.
|
29206657 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
|
29858004 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall use of any COPD regimen remained stable in the year following the formulary listing of LAMA/LABA combination products in May 2015, as did the use of LABA/ICS (most commonly-used regimen).
|
30261979 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study intends to establish the use of LABA/LAMA combination therapy in symptomatic patients with mild-to-moderate COPD by demonstrating the superiority of IND/GLY over tiotropium monotherapy.
|
28228162 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a real world setting of COPD treatment, the triple combination of LAMA, LABA and ICS inhalers is generally as effective as combining LAMA and LABA inhalers in preventing COPD exacerbations.
|
31759966 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β<sub>2</sub>-agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD).
|
31605923 |
2020 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The total average cost of COPD was €2647.38/patient and ICS/LABA/LAMA therapy contributed the most (€1541.45).
|
31174106 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first group of COPD patients (n = 30; mild (n = 3), moderate (n = 6), severe (n = 7), very severe (n = 14) as per GOLD II & III criteria was prescribed the standard therapy, a combination of (i) short acting anti-muscarinic agent (SAMA) + short acting β2 agonist (SABA) inhaled and (ii) corticosteroid inhaled (ICS) + long acting β2 agonist (LABA) (iii) ICS + LABA + LAMA.
|
31349003 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg is a twice-daily long-acting muscarinic receptor antagonist and long-acting β<sub>2</sub> agonist (LAMA/LABA) dual-bronchodilator maintenance therapy used to relieve symptoms and reduce future risk of exacerbations in adults with chronic obstructive pulmonary disease (COPD).
|
31096854 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Triple therapy with two bronchodilators (LABA plus LAMA) and an inhaled corticosteroid (ICS) is recommended for patients suffering from severe chronic obstructive pulmonary disease (COPD).
|
30463451 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the 12,906 articles found by searching the databases, we obtained data from 10,591 patients with COPD (LABA, n=5,058; LAMA, n=5,533) in seven published studies.
|
30746196 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD.
|
29322375 |
2018 |
|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: The use of LAMAs in asthma is now supported by pharmacological and clinical evidence, whereas the effectiveness of therapy with ICS/LABA/LAMA fixed dose combinations in patients with asthma still remains to be determined.
|
31422716 |
2019 |